Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Early Bird Ends

DAYS

HOURS

MINUTES

SECONDS

Back to Agenda

Session 10 Track 3: Real-World Case Studies in Oligonucleotide CMC Development and Commercialization

Vice President, Oligonucleotide and Small Molecule CMC

Denali Therapeutics, United States

Session 10 Track 3: Real-World Case Studies in Oligonucleotide CMC Development and Commercialization

Have an account?